Quantitative performance of antibody array technology in a prenatal screening setting.

Area of Science:

• Proteomics
• Biomarker Discovery
• Array Technology

Background:

• Antibody microarrays (Ab-arrays) are an innovative proteomics platform for high-throughput protein expression profiling in body fluids.
• Ab-arrays enable multiplexed measurements in small sample volumes, offering an alternative to conventional immunoassays like ELISA or DELFIA for analyzing multiple markers.
• Establishing sensitivity and quantitative performance is crucial for implementing Ab-arrays in clinical or population screening.

Purpose of the Study:

• To develop and optimize a duplex antibody microarray for simultaneous detection of pregnancy-associated plasma protein A (PAPP-A) and human chorion gonadotropin (fβ-hCG).
• To validate the performance of the developed Ab-array against the established AutoDelfia system for prenatal screening.

Main Methods:

• Development and optimization of a duplex Ab-array targeting PAPP-A and fβ-hCG.
• Analysis of serum samples from pregnant women across the dynamic range of both biomarkers.
• Validation of Ab-array results against the AutoDelfia system.

Main Results:

• The indirect labeling method demonstrated sensitive and quantitative performance for the duplex Ab-array.
• Low intra- and inter-assay variation was observed with the indirect labeling approach.
• The Ab-array performance was validated against the routine AutoDelfia system.

Conclusions:

• Ab-array technology shows promise as a viable alternative to ELISA or DELFIA for population screening.
• This method allows for simultaneous quantitative analysis of multiple biomarkers in small serum volumes.
• Antibody microarrays are well-suited for future high-throughput screening applications.